drugset
drugset / Trial / NCT00623974

Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

NCT00623974 ↗

Phase 2 Terminated 7 enrolled M.D. Anderson Cancer Center Eli Lilly and Company · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary Objective: -To identify the optimal dose of a seven-day course of twice-daily teriparatide as compared to standard therapy for hypocalcemia in patients after total thyroidectomy and/or extensive neck dissections (pharyngectomy, laryngectomy,unilateral, bilateral / central neck, mediastinal lymph node neck dissections), with which serum calcium will be raised to corrected serum calcium levels of 8-10.5mg/dL and maintained within this range until the end of the treatment course.

Timeline

Start
2008-05
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic 20 ug Subcutaneous
Subject Teriparatide Protein / enzyme biologic 40 ug Subcutaneous
Subject Teriparatide Protein / enzyme biologic 60 ug Subcutaneous
Background Calcitriol Small molecule 0.25 ug Oral
Background Calcium carbonate Other / unclassified 1000 mg Intravenous

Indications

No indication recorded.